NCT06383338RecruitingPhase 1
A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma.
A Prospective Feasibility Study Investigating PhEnoconversion of CYP3A4, CYP2C19 and CYP2D6 Genotype in Paediatric and Adolescent and Young Adult patientS With an acUte diagnosiS of Hodgkin or Non-Hodgkin Lymphoma.
Source: ClinicalTrials.gov · Last updated 27 Aug 2026
Brief summary (registry, in English)
PEGASUS aims to test acceptability and feasibility of studying phenoconversion (the change in metabolism phenotype) using probe medications in a paediatric oncology patient population. The study will be conducted in patients (6-25 years of age) with Hodgkin lymphoma or non-Hodgkin lymphoma as exemplar cohort, but with the understanding that cancer-directed and supportive care medicines of the CYP3A4, CYP2C19, and CYP2D6 metabolic pathways are commonly utilised for the treatment of many paediatric, adolescent, young adult, and adult cancers. The study involves administration of the probe medication at timepoints which align with pre-determined hospital visits for the treatment of lymphoma and subsequent blood draws to measure the metabolism of the probe medications. The acceptability and feasibility of this study will inform future studies in phenoconversion within the paediatric cancer population to direct more personalised precision medicine.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 21 Mar 2024
- Start date
- 22 Jul 2025
- Primary completion date
- Nov 2026
- Lead sponsor
- Murdoch Childrens Research Institute
- Diseases
- Hodgkin lymphoma, Childhood cancers
- NCT number
- NCT06383338
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 10
- From 22 Jul 2025 to the primary completion date, Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Has a known previous allergy to any of the probe medications (i.e., omeprazole or dextromethorphan).
- Had previous oncological treatment (not first cancer diagnosis).
- Any patient requiring urgent initiation of anti-cancer treatment outside hours where a member of the study staff is unable to approach the parent/guardian or participant for consent prior to commencing anti-cancer therapy will be ineligible for consent.
Other illness
- Failure to comply with inclusion criteria.
Other
- Common Terminology Criteria for Adverse Events (CTCAE) Grade IV end organ dysfunction (i.e., hepatic, renal, gastrointestinal).
- Is a clinically unstable patient requiring intensive care admission in high-risk circumstances will not be considered eligible for consent.
- Unable to provide written informed consent.
Who the study is looking for
- Age 6-25 years of age.
- New diagnosis of Hodgkin Lymphoma or Non-Hodgkin Lymphoma.
- Able to swallow and absorb oral or nasogastric tube (NGT) administration of probe drugs.
- Able to provide written informed consent.
Age in the registry: 6 years to 25 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peter MacCallum Cancer Centre Coordinator of this site? Confirm its status | Melbourne | Australia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.